What Decades of Estrogen Therapy May Mean for the Female Brain

Key takeaways

A large study followed more than 21,000 women, later cross-referencing brain scans, blood and spinal-fluid biomarkers, and autopsy results, and found that women who used estrogen-only hormone therapy later in life had markedly less protein buildup associated with cognitive aging in their brains.
Hormone therapy use was linked to 39% lower odds of a clinical cognitive-decline diagnosis and 35% lower odds of showing the hallmark protein changes (amyloid-beta plaques and tau tangles) at autopsy, compared with women who never used it.
This is an association from decades-old data, not a randomized trial, and the way hormone therapy was used back then (started around age 70) differs from how it's typically prescribed today (late 40s to early 50s) — so the researchers are clear this isn't yet a basis for brain-health recommendations.

A rare look inside the brain, decades later

Most research on hormone therapy and cognitive aging relies on memory tests or symptom reports collected while people are alive. This study did something less common: it combined that clinical data with actual brain tissue examined at autopsy in women, plus biomarker testing in blood and spinal fluid for hundreds more. That combination lets researchers see not just whether someone showed signs of cognitive decline, but what was physically happening in brain tissue underneath it.

Participants were followed for roughly three to five years starting at an average age of 71, with autopsies occurring at an average age of 82 — giving researchers a genuine end-of-life snapshot to work backward from.

What showed up in the tissue

Among women who had used estrogen-only hormone therapy, 18% showed no signs of the hallmark protein buildup associated with cognitive aging at autopsy, compared with 10% of women who never used it. On the other end, 40% of hormone therapy users showed the full pattern of that buildup, compared with 51% of nonusers. After adjusting for age, education, genetics, race, and blood pressure, hormone therapy use was associated with 35% lower odds of showing that pattern overall.

Biomarker testing in living participants told a consistent story: women who had used hormone therapy had blood and spinal-fluid readings suggesting less of that protein accumulating in the brain in the first place, not just less of it visible at autopsy years later.

Correlation, not yet causation

It's worth sitting with what this study can and can't say. The researchers were explicit that this shows an association, not proof that hormone therapy changes the trajectory of cognitive aging. And there's a meaningful wrinkle: the women in this data set typically started hormone therapy around age 70, whereas current medical guidance generally has women starting in their late 40s to early 50s and stopping by 60. That's a genuinely different biological window — starting therapy decades earlier, closer to the transition itself, could plausibly have a different effect than starting it after 70.

The lead researcher was candid about this limitation, noting that the findings are informative but may not translate directly to how hormone therapy is used today.

A longevity lens: hormones as an underexplored aging lever

This study adds to a growing body of work suggesting that hormonal shifts across the lifespan may play a larger role in long-term brain trajectory than previously appreciated. It's a useful reminder that "brain health" conversations often center on diet, exercise, and sleep — all genuinely important — while hormonal context sometimes gets left out of the picture entirely, especially for women navigating menopause.

None of this is a green light to start or continue hormone therapy specifically for brain-health reasons; that decision involves many other factors best worked through with a clinician. But it does suggest that the timing and hormonal landscape of a person's 40s, 50s, and 60s may echo further into brain aging than we've historically given it credit for.

The takeaway

The most useful signal here isn't "take estrogen for your brain" — the study itself doesn't support that leap. It's that hormonal exposure across the decades appears to be one more thread in the broader tapestry of long-term brain resilience, alongside metabolic health, movement, and cognitive engagement. As researchers continue studying hormone therapy under more current-day timing and protocols, we'll get a clearer picture of whether this association holds up — and, if so, when in life it matters most.

References:

Jennifer Bruno, Jacob S. Shaw, S.M. Hadi Hosseini. Association Between Menopausal Hormone Therapy and Alz Dis Neuropathology. Neurology, 2026; 107 (5). DOI: 10.1212/WNL.0000000000218413